FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800292469> ?p ?o ?g. }

• W2800292469 endingPage "718.e6" @default.
• W2800292469 startingPage "704" @default.
• W2800292469 abstract "Elbasvir (MK-8742) and grazoprevir (MK-5172; Merck & Co, Inc, Kenilworth, New Jersey) are hepatitis C virus (HCV)-specific inhibitors of the nonstructural protein 5A phosphoprotein and the nonstructural protein 3/4A protease, respectively. The aims of these studies were to evaluate the antiviral activity and safety of different doses of elbasvir or grazoprevir each administered as monotherapy to participants infected with either HCV genotype (GT) 1 or GT3.These 2 double-blind, randomized, placebo-controlled, sequential-panel, multiple ascending dose studies were conducted to assess the safety and pharmacodynamics of 5 days of once-daily elbasvir or 7 days of once-daily grazoprevir in adult male participants chronically infected with either HCV GT1 or GT3.Oral administration of elbasvir or grazoprevir once daily exhibited potent antiviral activity in participants with chronic GT1 or GT3 HCV infections. HCV RNA levels declined rapidly (within 1 day for elbasvir and 2 days for grazoprevir). At 50 mg of elbasvir once daily, the mean maximum reductions in HCV RNA from baseline were 5.21, 4.17, and 3.12 log10 IU/mL for GT1b-, GT1a-, and GT3-infected participants, respectively. At 100 mg of grazoprevir once daily, the mean maximum reductions in HCV RNA from baseline were 4.74 and 2.64 log10 IU/mL for GT1- and GT3-infected participants.The results in the elbasvir monotherapy study showed that 10 to 50 mg of elbasvir was associated with a rapid decline in HCV viral load; the results in the grazoprevir monotherapy study suggest that doses of 50 mg of grazoprevir and higher are on the maximum response plateau of the dose-response curve for GT1-infected participants. The results of these proof-of-concept studies provided preliminary data for the selection of the dosages of elbasvir and grazoprevir to test in Phase II and III clinical studies. ClinicalTrials.gov identifiers: NCT00998985 (Protocol 5172-004) and NCT01532973 (Protocol 8742-002)." @default.
• W2800292469 created "2018-05-17" @default.
• W2800292469 creator A5000575115 @default.
• W2800292469 creator A5004060087 @default.
• W2800292469 creator A5011296296 @default.
• W2800292469 creator A5013726991 @default.
• W2800292469 creator A5015071845 @default.
• W2800292469 creator A5018983745 @default.
• W2800292469 creator A5022689608 @default.
• W2800292469 creator A5025555714 @default.
• W2800292469 creator A5025618710 @default.
• W2800292469 creator A5028045704 @default.
• W2800292469 creator A5029825407 @default.
• W2800292469 creator A5034764399 @default.
• W2800292469 creator A5044409463 @default.
• W2800292469 creator A5045792987 @default.
• W2800292469 creator A5047745102 @default.
• W2800292469 creator A5048651841 @default.
• W2800292469 creator A5053678097 @default.
• W2800292469 creator A5056309593 @default.
• W2800292469 creator A5060272056 @default.
• W2800292469 creator A5065019304 @default.
• W2800292469 creator A5065535130 @default.
• W2800292469 creator A5069032543 @default.
• W2800292469 creator A5073601901 @default.
• W2800292469 creator A5074724094 @default.
• W2800292469 creator A5075756321 @default.
• W2800292469 creator A5088842832 @default.
• W2800292469 date "2018-05-01" @default.
• W2800292469 modified "2023-10-05" @default.
• W2800292469 title "Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3" @default.
• W2800292469 cites W1621802947 @default.
• W2800292469 cites W1871529692 @default.
• W2800292469 cites W1908153784 @default.
• W2800292469 cites W1980154502 @default.
• W2800292469 cites W1984413237 @default.
• W2800292469 cites W1995591620 @default.
• W2800292469 cites W2020007154 @default.
• W2800292469 cites W2023926449 @default.
• W2800292469 cites W2045877860 @default.
• W2800292469 cites W2054768505 @default.
• W2800292469 cites W2062749605 @default.
• W2800292469 cites W2063828224 @default.
• W2800292469 cites W2094778224 @default.
• W2800292469 cites W2100448657 @default.
• W2800292469 cites W2118684050 @default.
• W2800292469 cites W2122153421 @default.
• W2800292469 cites W2124733564 @default.
• W2800292469 cites W2125065061 @default.
• W2800292469 cites W2130921346 @default.
• W2800292469 cites W2131908790 @default.
• W2800292469 cites W2161578383 @default.
• W2800292469 cites W2163028749 @default.
• W2800292469 cites W2164439784 @default.
• W2800292469 cites W2171945301 @default.
• W2800292469 cites W2277092291 @default.
• W2800292469 cites W2289590795 @default.
• W2800292469 cites W2295408863 @default.
• W2800292469 cites W2518041763 @default.
• W2800292469 cites W2537433074 @default.
• W2800292469 cites W2586420967 @default.
• W2800292469 cites W2605861831 @default.
• W2800292469 cites W2610278579 @default.
• W2800292469 cites W2765212316 @default.
• W2800292469 doi "https://doi.org/10.1016/j.clinthera.2018.03.002" @default.
• W2800292469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29703432" @default.
• W2800292469 hasPublicationYear "2018" @default.
• W2800292469 type Work @default.
• W2800292469 sameAs 2800292469 @default.
• W2800292469 citedByCount "5" @default.
• W2800292469 countsByYear W28002924692019 @default.
• W2800292469 countsByYear W28002924692020 @default.
• W2800292469 countsByYear W28002924692021 @default.
• W2800292469 crossrefType "journal-article" @default.
• W2800292469 hasAuthorship W2800292469A5000575115 @default.
• W2800292469 hasAuthorship W2800292469A5004060087 @default.
• W2800292469 hasAuthorship W2800292469A5011296296 @default.
• W2800292469 hasAuthorship W2800292469A5013726991 @default.
• W2800292469 hasAuthorship W2800292469A5015071845 @default.
• W2800292469 hasAuthorship W2800292469A5018983745 @default.
• W2800292469 hasAuthorship W2800292469A5022689608 @default.
• W2800292469 hasAuthorship W2800292469A5025555714 @default.
• W2800292469 hasAuthorship W2800292469A5025618710 @default.
• W2800292469 hasAuthorship W2800292469A5028045704 @default.
• W2800292469 hasAuthorship W2800292469A5029825407 @default.
• W2800292469 hasAuthorship W2800292469A5034764399 @default.
• W2800292469 hasAuthorship W2800292469A5044409463 @default.
• W2800292469 hasAuthorship W2800292469A5045792987 @default.
• W2800292469 hasAuthorship W2800292469A5047745102 @default.
• W2800292469 hasAuthorship W2800292469A5048651841 @default.
• W2800292469 hasAuthorship W2800292469A5053678097 @default.
• W2800292469 hasAuthorship W2800292469A5056309593 @default.
• W2800292469 hasAuthorship W2800292469A5060272056 @default.
• W2800292469 hasAuthorship W2800292469A5065019304 @default.
• W2800292469 hasAuthorship W2800292469A5065535130 @default.
• W2800292469 hasAuthorship W2800292469A5069032543 @default.
• W2800292469 hasAuthorship W2800292469A5073601901 @default.
• W2800292469 hasAuthorship W2800292469A5074724094 @default.

• next